Genmab As (GMAB) SEC Filing 20-F Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

GMAB Annual Reports

  • 20-F Annual Report February 2022
  • 20-F Annual Report March 2021
    20-F Annual Report March 2020

Genmab As

CIK: 1434265 Ticker: GMAB

View differences made from one year to another to evaluate Genmab As's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Genmab As.


Assess how Genmab As's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Genmab As's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: GMAB
CIK: 1434265
Form Type: 20-F Annual Report
Accession Number: 0001558370-22-001256
Submitted to the SEC: Wed Feb 16 2022 1:56:43 PM EST
Accepted by the SEC: Wed Feb 16 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: